Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Daniel on +44 1494 818 004 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now

I just thought I would drop you a note with a BIG THANK YOU for all your help over the last few months. I have been very impressed with Zenoap's professionalism.
Paula, 2011

Covidien to buy interventional pulmonology specialist superDimension

20 March 2012 00:00 in Medical Company Restructures

Covidien has announced the acquisition of superDimension, a specialist developer of minimally invasive interventional pulmonology devices, for $300 million (189.24 million pounds).

The Israel-based business is responsible for developing the i-Logic System, a device which offers access to lesions deep in the lungs as well as mediastinal lymph nodes, generating around $30 million in annual sales.

superDimension's product uses electromagnetic navigation bronchoscopy technology to extend the reach of traditional bronchoscopes, thus enabling more effective biopsies and better evaluation of lung lesions.

The takeover is expected to be completed in the second quarter of 2012 and will see superDimension become part of Covidien's endomechanical portfolio.

Bryan Hanson, president of surgical solutions at Covidien, said: "The acquisition of superDimension will position Covidien to continue its investment in meaningful innovation by delivering more comprehensive solutions in the evaluation and treatment of lung diseases."

This week also saw the company appoint Richard DeRisio as its new vice-president, for global quality assurance and regulatory affairs, effective immediately.ADNFCR-8000103-ID-801322017-ADNFCR

Other news stories from 20/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd